Equities research analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $75.59 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sucampo Pharmaceuticals’ earnings. The lowest sales estimate is $73.00 million and the highest is $77.70 million. Sucampo Pharmaceuticals reported sales of $73.02 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.5%. The firm is expected to issue its next earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $75.59 million for the current fiscal year, with estimates ranging from $250.00 million to $255.10 million. For the next fiscal year, analysts anticipate that the company will post sales of $261.10 million per share, with estimates ranging from $257.49 million to $263.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 earnings per share.

Several research analysts recently weighed in on the company. BidaskClub upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Leerink Swann reiterated a “market perform” rating and issued a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, January 2nd. Nomura assumed coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $43.00 price objective for the company. B. Riley increased their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Finally, UBS Group lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research report on Friday, January 5th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $20.25.

Sucampo Pharmaceuticals (SCMP) opened at $17.98 on Friday. The firm has a market capitalization of $846.67 and a P/E ratio of -5.46. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $18.75. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.13% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gamco Investors INC. ET AL purchased a new position in shares of Sucampo Pharmaceuticals during the fourth quarter worth $528,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Sucampo Pharmaceuticals in the fourth quarter valued at $2,978,000. Gabelli Funds LLC acquired a new stake in shares of Sucampo Pharmaceuticals in the fourth quarter valued at $5,403,000. Alambic Investment Management L.P. raised its stake in shares of Sucampo Pharmaceuticals by 453.3% in the fourth quarter. Alambic Investment Management L.P. now owns 101,800 shares of the biopharmaceutical company’s stock valued at $1,827,000 after acquiring an additional 83,400 shares in the last quarter. Finally, Engineers Gate Manager LP raised its stake in shares of Sucampo Pharmaceuticals by 367.5% in the fourth quarter. Engineers Gate Manager LP now owns 261,931 shares of the biopharmaceutical company’s stock valued at $4,702,000 after acquiring an additional 205,901 shares in the last quarter. Institutional investors and hedge funds own 65.01% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “$75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/75-59-million-in-sales-expected-for-sucampo-pharmaceuticals-inc-scmp-this-quarter/1840788.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.